| scholarly article | Q13442814 |
| P2093 | author name string | G Sachs | |
| J M Shin | |||
| M Besancon | |||
| A Simon | |||
| P2860 | cites work | Asp804 and Asp808 in the transmembrane domain of the Na,K-ATPase alpha subunit are cation coordinating residues | Q41150449 |
| The mechanism for inhibition of gastric (H+ + K+)-ATPase by omeprazole | Q41361455 | ||
| Glutamic acid 327 in the sheep alpha 1 isoform of Na+,K(+)-ATPase is a pivotal residue for cation-induced conformational changes | Q41918971 | ||
| Amino-acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence | Q48376136 | ||
| Affinity of the (Na+ plus K+)-dependent ATPase for Na+ measured by Na+-modified enzyme inactivation | Q48586515 | ||
| On the reversibility of binding of cardiotonic steroids to a partially purified (Na+K)-activated adenosinetriphosphatase from beef brain | Q48902521 | ||
| Site-directed mutagenesis of the cysteine residues in the Neurospora crassa plasma membrane H(+)-ATPase. | Q54595444 | ||
| Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa | Q27861105 | ||
| The pharmacology of the gastric acid pump: the H+,K+ ATPase | Q28292372 | ||
| Analysis of thiol-topography in Na,K-ATPase using labelling with different maleimide nitroxide derivatives | Q30333825 | ||
| Membrane disposition of the M5-M6 hairpin of Na+,K(+)-ATPase alpha subunit is ligand dependent. | Q34018696 | ||
| The site of action of pantoprazole in the gastric H+/K(+)-ATPase | Q34356114 | ||
| Chemical modification of Glu-953 of the alpha chain of Na+,K(+)-ATPase associated with inactivation of cation occlusion | Q37127272 | ||
| The mechanism and structure of the gastric H,K-ATPase | Q37876715 | ||
| Quantitation of hydrogen ion and potential gradients in gastric plasma membrane vesicles | Q39207142 | ||
| Active transport of Na + and K + through animal cell membranes | Q39895427 | ||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 22438-22446 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. | |
| P478 | volume | 272 |
| Q46679812 | A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences |
| Q43691957 | A model of reversible inhibitors in the gastric H+/K+-ATPase binding site determined by rotational echo double resonance NMR. |
| Q36661321 | A review of rabeprazole in the treatment of acid-related diseases |
| Q36809334 | ATP4A gene regulatory network for fine-tuning of proton pump and ion channels |
| Q44488906 | Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors |
| Q56387193 | Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome |
| Q34079152 | Activation of human CIC-2 Cl- channels: implications for cystic fibrosis |
| Q40800285 | Alanine-scanning mutagenesis of the sixth transmembrane segment of gastric H+,K+-ATPase alpha-subunit |
| Q33723249 | Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites |
| Q33948811 | Antiplatelet drug interactions with proton pump inhibitors |
| Q28833519 | Benzimidazole covalent probes and the gastric H(+)/K(+)-ATPase as a model system for protein labeling in a copper-free setting |
| Q43515400 | Biochemical properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-. |
| Q37646785 | CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. |
| Q35429956 | Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). |
| Q78069543 | Chimeric domain analysis of the compatibility between H(+), K(+)-ATPase and Na(+),K(+)-ATPase beta-subunits for the functional expression of gastric H(+),K(+)-ATPase |
| Q37535425 | Chloride channelopathies of ClC-2. |
| Q40799825 | ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole |
| Q34509642 | Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor |
| Q35603768 | Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know |
| Q44692617 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study |
| Q33855564 | Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity |
| Q37122451 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis |
| Q40901986 | Comparison of covalent with reversible inhibitor binding sites of the gastric H,K-ATPase by site-directed mutagenesis |
| Q39440440 | Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study |
| Q39445198 | Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group |
| Q44545173 | Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? |
| Q53590651 | Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. |
| Q27666553 | Conformational rearrangement of gastric H(+),K(+)-ATPase induced by an acid suppressant |
| Q72992516 | Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole |
| Q52536103 | Cys(577) is a conformationally mobile residue in the ATP-binding domain of the Na,K-ATPase alpha-subunit. |
| Q97681494 | DNA unchained: two assays to discover and study inhibitors of the DNA clustering function of barrier-to-autointegration factor |
| Q43734552 | Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole |
| Q38056614 | Do proton pump inhibitors protect against cancer progression in GERD? |
| Q45773103 | Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity |
| Q43514780 | Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers |
| Q34370499 | Dyspepsia: challenges in diagnosis and selection of treatment |
| Q44282409 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin |
| Q39345807 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment |
| Q43817651 | Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. |
| Q44148251 | Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers |
| Q79931939 | Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects |
| Q42468861 | Effects of streptozotocin-induced long-term diabetes on parietal cell function and morphology in rats |
| Q34229235 | Efficacy of rabeprazole once daily for acid-related disorders |
| Q46952514 | Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype |
| Q44364920 | Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo |
| Q37755220 | Esomeprazole: potent acid suppression in the treatment of acid-related disorders |
| Q39404002 | Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases |
| Q33772171 | Formulary management of proton pump inhibitors |
| Q46791650 | Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy |
| Q38111736 | Gastric H+,K+-ATPase |
| Q36463113 | Gastric H,K-ATPase as a drug target |
| Q38072903 | Gastric acid, calcium absorption, and their impact on bone health |
| Q37188528 | Gastric epithelial cell modality and proton pump inhibitor |
| Q42116901 | Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia |
| Q37425645 | H+/K+ ATPase inhibitors in the treatment of acid-related disorders |
| Q30708883 | H,K-ATPase alpha subunit C-terminal membrane topology: epitope tags in the insect cell expression system |
| Q41037593 | Identification of the site of inhibition by omeprazole of a alpha-beta fusion protein of the H,K-ATPase using site-directed mutagenesis. |
| Q42364580 | Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects |
| Q46596438 | Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels |
| Q37672746 | Lymphocytic colitis associated with lansoprazole treatment |
| Q33850189 | Medical therapy. Management of the refractory patient |
| Q36799925 | Microscopic colitis associated with lansoprazole: report of two cases and a review of the literature |
| Q35070154 | Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics |
| Q40742973 | Mutational study on the roles of disulfide bonds in the beta-subunit of gastric H+,K+-ATPase |
| Q33536467 | NMR of drugs and ligands bound to membrane receptors |
| Q39378387 | New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases? |
| Q36120771 | Novel approaches to the pharmacological blockade of gastric acid secretion |
| Q39409884 | Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis |
| Q35033819 | Ouabain affinity determining residues lie close to the Na/K pump ion pathway |
| Q35028387 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders |
| Q34284529 | Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. |
| Q37201668 | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori |
| Q36542670 | Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. |
| Q35558230 | Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. |
| Q35572512 | Pharmacologic properties of proton pump inhibitors |
| Q35572508 | Physiology of the parietal cell and therapeutic implications |
| Q50680833 | Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. |
| Q46136802 | Point mutations in the extracytosolic loop between transmembrane segments M5 and M6 of the yeast Pma1 H+-ATPase: alanine-scanning mutagenesis |
| Q33222162 | Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. |
| Q47827584 | Proton pump inhibitors have pH-dependent effects on the thermostability of the carboxyl-terminal domain of voltage-gated proton channel Hv1. |
| Q38091317 | Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics |
| Q39298225 | Proton pump inhibitors in the management of GERD. |
| Q34181922 | Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease |
| Q34475730 | Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders |
| Q36616851 | Quadruple therapy for eradication of Helicobacter pylori |
| Q40651737 | Quantity and Quality Control of Gastric Proton Pump in the Endoplasmic Reticulum by Ubiquitin/Proteasome System |
| Q41722683 | Rabeprazole |
| Q44700487 | Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression |
| Q35167717 | Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety |
| Q45980662 | Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.". |
| Q38958255 | Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines |
| Q38038691 | Rabeprazole for the treatment of acid-related disorders |
| Q39405474 | Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial |
| Q43605878 | Rabeprazole is superior to omeprazole for the inhibition of peptone meal‐stimulated gastric acid secretion in Helicobacter pylori‐negative subjects |
| Q51557054 | Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. |
| Q39430555 | Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group |
| Q39422116 | Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease |
| Q56431955 | Rabeprazole: a pharmacologic and clinical review for acid-related disorders |
| Q46203790 | Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease |
| Q43946238 | Rabeprazole: quest for the best PPI. |
| Q36322095 | Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication |
| Q42868371 | Relationship between the Acid-Inhibitory Effects of Two Proton Pump Inhibitors and CYP2C19 Genotype in Japanese Subjects: A Randomized Two-Way Crossover Study |
| Q33912651 | Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. |
| Q35923964 | Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders |
| Q34534323 | Review article: rabeprazole-based therapy in Helicobacter pylori eradication |
| Q35923954 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole |
| Q34526068 | Review article: the clinical pharmacology of proton pump inhibitors |
| Q35923949 | Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications |
| Q33734837 | Review article: the pharmacology of rabeprazole |
| Q38237417 | Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. |
| Q95818672 | Safety of the long-term use of proton pump inhibitors |
| Q37406226 | Secretory state regulates Zn2+ transport in gastric parietal cell of the rabbit |
| Q38313317 | Site-directed chemical labeling of extracellular loops in a membrane protein. The topology of the Na,K-ATPase alpha-subunit |
| Q39378798 | Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease |
| Q77726336 | Stabilization of the H,K-ATPase M5M6 membrane hairpin by K+ ions. Mechanistic significance for p2-type atpases |
| Q35707833 | Stress-related mucosal disease: risk factors and prophylactic therapy |
| Q34271890 | Structural similarities of Na,K-ATPase and SERCA, the Ca(2+)-ATPase of the sarcoplasmic reticulum |
| Q82619512 | Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers |
| Q39386649 | Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole |
| Q56675654 | The Taxonomy of Covalent Inhibitors |
| Q44709166 | The cavity structure for docking the K(+)-competitive inhibitors in the gastric proton pump |
| Q41141210 | The cryo-EM structure of gastric H+,K+-ATPase with bound BYK99, a high-affinity member of K+-competitive, imidazo[1,2-a]pyridine inhibitors |
| Q41829313 | The negative charge of glutamic acid-820 in the gastric H+,K+-ATPase alpha-subunit is essential for K+ activation of the enzyme activity |
| Q35003805 | The pharmacology and clinical relevance of proton pump inhibitors |
| Q33915562 | The proton-pump inhibitors: similarities and differences |
| Q46387232 | The role of the third extracellular loop of the Na+,K+-ATPase alpha subunit in a luminal gating mechanism |
| Q35039109 | The use of proton pump inhibitors in children: a comprehensive review |
| Q33557158 | Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole |
| Q33594850 | Treatment of Helicobacter pylori infection: current status and future concepts |
| Q35031744 | Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors |
Search more.